LSBCF (LakeShore Biopharma Co) Short-Term Debt: $53.86 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Short-Term Debt?

LakeShore Biopharma Co LSBCF Short-Term Debt is $53.86 Mil as of Mar. 2025.

LakeShore Biopharma Co's Short-Term Debt for the quarter that ended in Mar. 2025 was $53.86 Mil.

LakeShore Biopharma Co's quarterly Short-Term Debt declined from Mar. 2024 ($44.23 Mil) to Sep. 2024 ($40.74 Mil) but then increased from Sep. 2024 ($40.74 Mil) to Mar. 2025 ($53.86 Mil).

LakeShore Biopharma Co's annual Short-Term Debt increased from Mar. 2023 ($28.12 Mil) to Mar. 2024 ($44.23 Mil) and increased from Mar. 2024 ($44.23 Mil) to Mar. 2025 ($53.86 Mil).

LakeShore Biopharma Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

LakeShore Biopharma Co Short-Term Debt Related Terms

LakeShore Biopharma Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Short-Term Debt Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Short-Term Debt
0.00 17.61 28.12 44.23 53.86

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 28.12 25.04 44.23 40.74 53.86
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $53.86 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Short-Term Debt of $53.86 Mil as of Mar. 2025.
Is LakeShore Biopharma Co's Short-Term Debt too high?
LakeShore Biopharma Co's current Short-Term Debt is $53.86 Mil.
How does LakeShore Biopharma Co's Short-Term Debt compare to ACUT and PPCB?
LakeShore Biopharma Co's Short-Term Debt of $53.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. LakeShore Biopharma Co's current Short-Term Debt is $53.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Short-Term Debt of $53.86 Mil. The current Short-Term Debt is $53.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Short-Term Debt is $53.86 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.